BARI 2D: A Reanalysis Focusing on Cardiovascular Events.

Area of Science:

• Cardiology
• Endocrinology
• Clinical Trials

Background:

• Type 2 diabetes mellitus and stable coronary artery disease pose significant cardiovascular risks.
• Optimal treatment strategies for this patient population require further investigation.
• The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial previously explored different therapeutic approaches.

Purpose of the Study:

• To reanalyze the BARI 2D trial data.
• To evaluate a new composite cardiovascular disease (CVD) outcome.
• To determine the optimal treatment strategy for patients with type 2 diabetes and stable coronary artery disease.

Main Methods:

• Reanalysis of the BARI 2D trial data involving 2368 patients with type 2 diabetes and coronary artery disease.
• Patients were randomized to insulin-sensitizing (IS) or insulin-providing (IP) therapy and to revascularization (REV) or intensive medical therapy (MED).
• A composite outcome of 8 CVD events was used to assess treatment efficacy over four years.

Main Results:

• Insulin-sensitizing (IS) therapy was associated with significantly lower 4-year composite CVD rates (35.8%) compared to insulin-providing (IP) therapy (41.6%; P=.004).
• Revascularization (REV) also significantly reduced 4-year composite CVD rates (32.7%) compared to intensive medical therapy (MED) (44.7%; P<.001).
• The combination of IS therapy and REV showed the lowest composite CVD rates (17.3%), particularly in patients selected for coronary artery bypass grafting (CABG).

Conclusions:

• Both IS therapy and REV independently reduce cardiovascular events in patients with type 2 diabetes and coronary artery disease.
• The combination of IS therapy and CABG demonstrates the lowest risk of subsequent CVD events.
• These findings support tailored treatment strategies combining specific drug therapies with revascularization approaches for improved cardiovascular outcomes.